HE4 CRISPR Activation Plasmid (m): sc-426693-ACT
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- HE4 CRISPR Activation Plasmid (m) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- HE4 CRISPR Activation Plasmid (m) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by HE4 CRISPR Activation Plasmid (m) and HE4 CRISPR Activation Plasmid (m2) target distinct regulatory regions upstream of the Wfdc2 transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HE4 CRISPR Activation Plasmid (m) | sc-426693-ACT | 20 µg | $397.00 |
Mouse Wfdc2 encodes HE4, a secreted whey acidic protein domain–containing glycoprotein implicated in extracellular protease regulation and epithelial cell homeostasis. HE4 is linked to remodeling of the pericellular matrix and modulation of inflammatory signaling, processes that influence tissue architecture, barrier function, and cell–cell communication. In experimental systems, altered HE4 expression is associated with changes in proliferation, migration, and differentiation programs in epithelial compartments. These features make Wfdc2 a useful molecular handle for studying proteostasis at the cell surface and pathway crosstalk between secreted factors and intracellular transcriptional responses.
HE4 CRISPR Activation Plasmid (m) provides a targeted, non-destructive approach to upregulating endogenous Wfdc2 expression without altering the underlying DNA sequence.
HE4 CRISPR Activation Plasmid (m) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the Wfdc2 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the Wfdc2 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous HE4 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native Wfdc2 locus and enabling the study of HE4-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of HE4 pathway restoration in tumor cells with silenced or reduced Wfdc2 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.